Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis
Medicines · 29.09.2020 · 7 (10) · 62
DOI: 10.3390/medicines7100062 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medicines, online erschienen am 29.09.2020. Verfasst von Rolf Teschke und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, D-63450 Hanau, Teaching Hospital of the Medical Facu…. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 257 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
A large number of idiosyncratic drug induced liver injury (iDILI) and herb induced liver injury(HILI) cases of variable quality has been published but some are a matter of concern if the cases were not evaluated for causality using a robust causality assessment method (CAM) such as RUCAM (Roussel Uclaf Causality Assessment Method) as diagnostiinjuryc algorithm. The purpose of this analysis was to evaluate the worldwide use of RUCAM in iDILI and HILI cases.
Methods
The PubMed database (1993–30 June 2020) was searched for articles by using the following key terms: Roussel Uclaf Causality Assessment Method; RUCAM; Idiosyncratic drug induced liver injury; iDILI; Herb induced liver injury; HILI.
Results
Considering reports published worldwide since 1993, our analysis showed the use of RUCAM for causality assessment in 95,885 cases of liver injury including 81,856 cases of idiosyncratic DILI and 14,029 cases of HILI. Among the top countries providing RUCAM based DILI cases were, in decreasing order, China, the US, Germany, Korea, and Italy, with China, Korea, Germany, India, and the US as the top countries for HILI.
Conclusions
Since 1993 RUCAM is certainly the most widely used method to assess causality in IDILI and HILI. This should encourage practitioner, experts, and regulatory agencies to use it in order to reinforce their diagnosis and to take sound decisions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, D-63450 Hanau, Teaching Hospital of the Medical Faculty of the Goethe University, D-60590 Frankfurt/Main, Germany.
- Pharmacovigilance Consultancy, F-75020 Paris, France.
ORCID-Profile: Rolf Teschke, Gaby Danan
Zitieren
APA
Teschke, R., & Danan, G. (2020). Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis. Medicines, 7(10), 62. https://doi.org/10.3390/medicines7100062
Vancouver
Teschke R, Danan G. Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis. Medicines. 2020;7(10):62. doi:10.3390/medicines7100062
BibTeX
@article{Teschke2020,
author = {Teschke, Rolf and Danan, Gaby},
title = {Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993–Mid 2020: A Comprehensive Analysis},
journal = {Medicines},
year = {2020},
volume = {7},
number = {10},
pages = {62},
doi = {10.3390/medicines7100062}
}
EUVIMED